Irma M. Oving

4.7k total citations · 2 hit papers
21 papers, 3.6k citations indexed

About

Irma M. Oving is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Irma M. Oving has authored 21 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 7 papers in Cancer Research. Recurrent topics in Irma M. Oving's work include Prostate Cancer Treatment and Research (7 papers), Cancer Treatment and Pharmacology (6 papers) and HER2/EGFR in Cancer Research (4 papers). Irma M. Oving is often cited by papers focused on Prostate Cancer Treatment and Research (7 papers), Cancer Treatment and Pharmacology (6 papers) and HER2/EGFR in Cancer Research (4 papers). Irma M. Oving collaborates with scholars based in Netherlands, Italy and Switzerland. Irma M. Oving's co-authors include Hans Clevers, Marc van de Wetering, Maaike van den Born, Anna-Pavlina G. Haramis, Gwen Soete, Cornelis L. Verweij, Martin Eilers, Adam Hurlstone, Wim de Lau and Petra Moerer and has published in prestigious journals such as Cell, Journal of Clinical Oncology and Gastroenterology.

In The Last Decade

Irma M. Oving

19 papers receiving 3.5k citations

Hit Papers

The β-Catenin/TCF-4 Complex Imposes a Crypt Progenitor Ph... 2002 2026 2010 2018 2002 2009 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The β-Catenin/TCF-4 Complex Imposes a Crypt Progenitor Phenotype on Colorectal Cancer Cells
    2002 1.6k citations Marc van de Wetering, Elena Sancho et al. Cell profile →
  2. Transcription Factor Achaete Scute-Like 2 Controls Intestinal Stem Cell Fate
    2009 546 citations Laurens G. van der Flier, Mariëlle van Gijn et al. Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Irma M. Oving Netherlands 11 2.4k 1.5k 741 631 483 21 3.6k
Norbert Schweifer Austria 28 2.8k 1.2× 1.1k 0.8× 1.1k 1.5× 660 1.0× 283 0.6× 46 4.0k
Koei Chin United States 27 2.2k 0.9× 876 0.6× 812 1.1× 1.0k 1.6× 249 0.5× 65 3.4k
Barbara Stecca Italy 32 3.2k 1.3× 1.2k 0.8× 516 0.7× 390 0.6× 328 0.7× 65 3.8k
Jordi Camps Spain 29 1.4k 0.6× 769 0.5× 357 0.5× 908 1.4× 477 1.0× 87 2.6k
Torben F. Ørntoft Denmark 13 2.5k 1.0× 1.5k 1.0× 351 0.5× 741 1.2× 702 1.5× 20 3.6k
Young Kyung Bae South Korea 26 1.1k 0.5× 944 0.6× 320 0.4× 691 1.1× 384 0.8× 122 2.5k
Robert Winqvist Finland 34 2.1k 0.8× 936 0.6× 1.1k 1.5× 853 1.4× 479 1.0× 89 3.3k
Ron Firestein United States 35 2.9k 1.2× 1.2k 0.8× 304 0.4× 679 1.1× 294 0.6× 59 4.3k
Brigitte M. Pützer Germany 41 2.9k 1.2× 1.9k 1.3× 491 0.7× 905 1.4× 129 0.3× 112 4.3k
Toby J. Phesse United Kingdom 23 1.9k 0.8× 1.1k 0.7× 421 0.6× 508 0.8× 340 0.7× 44 3.1k

Countries citing papers authored by Irma M. Oving

Since Specialization
Citations

This map shows the geographic impact of Irma M. Oving's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Irma M. Oving with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Irma M. Oving more than expected).

Fields of papers citing papers by Irma M. Oving

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Irma M. Oving. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Irma M. Oving. The network helps show where Irma M. Oving may publish in the future.

Co-authorship network of co-authors of Irma M. Oving

This figure shows the co-authorship network connecting the top 25 collaborators of Irma M. Oving. A scholar is included among the top collaborators of Irma M. Oving based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Irma M. Oving. Irma M. Oving is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bosch, D. Andries, Irma M. Oving, Wim J.G. Oyen, et al.. (2024). The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of223Ra Therapy in Metastatic Castration-Resistant Prostate Cancer Patients. Journal of Nuclear Medicine. 65(4). 541–547. 2 indexed citations
2.
Tolmeijer, Sofie H., Sandra van Wilpe, Maartje J. Geerlings, et al.. (2023). Early On-treatment Circulating Tumor DNA Measurements and Response to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer. European Urology Oncology. 7(2). 282–291. 10 indexed citations
3.
Vissers, Pauline A. J., Willemieke P.M. Dijksterhuis, David Bertwistle, et al.. (2023). Comparing treatment and outcomes in advanced esophageal, gastroesophageal junction, and gastric adenocarcinomas: a population-based study. Therapeutic Advances in Medical Oncology. 15. 2607312–2607312. 3 indexed citations
4.
Bosch, D. Andries, Koos van der Velden, Irma M. Oving, et al.. (2023). 1823P The impact of baseline PSMA PET/CT vs. CT on outcomes of Radium-223 therapy in mCRPC patients. Annals of Oncology. 34. S987–S988.
5.
Doelen, Maarten J. van der, Irma M. Oving, Jean‐Paul van Basten, et al.. (2022). Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy. Prostate Cancer and Prostatic Diseases. 26(1). 142–150. 8 indexed citations
6.
7.
Zande, Kim van der, Vincent van der Noort, Paul Hamberg, et al.. (2021). First results from a randomized phase II study of cabazitaxel (CBZ) versus an androgen receptor targeted agent (ARTA) in patients with poor-prognosis castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 39(15_suppl). 5059–5059. 3 indexed citations
8.
Oort, Inge M. van, Gerald W. Verhaegh, Anton F. J. de Haan, et al.. (2021). RNA Biomarkers as a Response Measure for Survival in Patients with Metastatic Castration-Resistant Prostate Cancer. Cancers. 13(24). 6279–6279. 6 indexed citations
9.
10.
Voort, Anna van der, Mette S. van Ramshorst, Erik van Werkhoven, et al.. (2020). Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2-positive breast cancer (TRAIN-2): A randomized phase III trial.. Journal of Clinical Oncology. 38(15_suppl). 501–501. 24 indexed citations
11.
Ramshorst, Mette S. van, Anna van der Voort, Erik van Werkhoven, et al.. (2018). Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology. 19(12). 1630–1640. 245 indexed citations
12.
Ramshorst, Mette S. van, Erik van Werkhoven, Ingrid A.M. Mandjes, et al.. (2017). A phase III trial of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2+ breast cancer: The TRAIN-2 study (BOOG 2012-03).. Journal of Clinical Oncology. 35(15_suppl). 507–507. 5 indexed citations
13.
Ramshorst, Mette S. van, Erik van Werkhoven, Aafke H. Honkoop, et al.. (2016). Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study. The Breast. 29. 153–159. 28 indexed citations
14.
Flier, Laurens G. van der, Mariëlle van Gijn, Pantelis Hatzis, et al.. (2009). Transcription Factor Achaete Scute-Like 2 Controls Intestinal Stem Cell Fate. Cell. 136(5). 903–912. 546 indexed citations breakdown →
15.
Flier, Laurens G. van der, Jacob Sabates–Bellver, Irma M. Oving, et al.. (2006). The Intestinal Wnt/TCF Signature. Gastroenterology. 132(2). 628–632. 385 indexed citations
16.
Wetering, Marc van de, Irma M. Oving, Vanesa Muncan, et al.. (2003). Specific inhibition of gene expression using a stably integrated, inducible small‐interfering‐RNA vector. EMBO Reports. 4(6). 609–615. 440 indexed citations
17.
Wetering, Marc van de, Elena Sancho, Cornelis L. Verweij, et al.. (2002). The β-Catenin/TCF-4 Complex Imposes a Crypt Progenitor Phenotype on Colorectal Cancer Cells. Cell. 111(2). 241–250. 1642 indexed citations breakdown →
18.
Oving, Irma M. & Hans Clevers. (2002). Molecular causes of colon cancer. European Journal of Clinical Investigation. 32(6). 448–457. 112 indexed citations
19.
Kluin‐Nelemans, Hanneke C., P. M. Kluin, Ed Schuuring, et al.. (1997). Characterization of a novel malignant B cell line with t(14;18) and t(4;11) established from a patient with acute monoblastic leukemia.. PubMed. 25(10). 1062–8. 1 indexed citations
20.
Kluin‐Nelemans, Hanneke C., et al.. (1994). Abnormally activated T lymphocytes in the spleen of patients with hairy-cell leukemia.. PubMed. 8(12). 2095–101. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Norbert Schweifer Breakdown of academic impact, for papers by Koei Chin Breakdown of academic impact, for papers by Barbara Stecca Breakdown of academic impact, for papers by Jordi Camps Breakdown of academic impact, for papers by Torben F. Ørntoft Breakdown of academic impact, for papers by Young Kyung Bae Breakdown of academic impact, for papers by Robert Winqvist Breakdown of academic impact, for papers by Ron Firestein Breakdown of academic impact, for papers by Brigitte M. Pützer Breakdown of academic impact, for papers by Toby J. Phesse
Rankless by CCL
2026